AlphAIAlphAI — Financial news for AI agents
tradingview.com$AMLX

Amylyx Pharmaceuticals 3Q 2026: EPS ($0.38) — 10-Q Summary

Amylyx Pharmaceuticals reported no product revenue in Q3 2026, with a net loss of $45.49M, up 32.3% YoY. Higher R&D costs were partially offset by increased interest income. Avexitide's Phase 3 trial met its primary endpoint, and the company plans an NDA submission by year-end 2026. AMX0114 and AMX0318 are in early stages of development.

Original reporting
tradingview.com
Published Nov 5, 2026, 12:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Amylyx Pharmaceuticals 3Q 2026: EPS ($0.38) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$AMLXBearishHigh
01

Why it matters

The earnings miss may trigger short‑term sell‑off, but the successful LUCIDITY trial offers long‑term upside.

02

Market read

First‑report earnings data for a small‑cap biotech, providing fresh pricing input.

03

What to watch

Potential upside from upcoming NDA submission and 2027 launch expectations.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Amylyx Pharmaceuticals filed its Q3 2026 10‑Q, reporting no product revenue and a net loss of $45.5M.

Company-level read

Ticker impact

$AMLXBearishHigh confidence
Context

Q3 2026 10-Q shows widened net loss and EPS of -$0.38, with no product revenue and higher R&D spend.

Expected impact

likely downward pressure as market prices in the widened loss

Evidence & confidence

The disclosed loss increase and lack of revenue are fresh negative fundamentals.

Market effects

Sector

Biotech sector may see broader risk aversion due to loss widening.

Regional

US biotech investors may adjust exposure.

Global

Limited to investors tracking small-cap biotech earnings.

Counterpoint

What could challenge this read

Positive Phase 3 trial data could offset loss concerns if FDA approval materializes.

Key entities

  • company
    Amylyx Pharmaceuticals

    Biotech firm developing avexitide.

Read at source← All news

StoryAmylyx reports no product revenue as avexitide FDA filing remains on track

Also covered by

1 outlet

Related articles

$AMLXMedAI 8/10

Amylyx Pharmaceuticals Q3 Earnings Call Highlights

Amylyx Pharmaceuticals reported Q3 operating expenses rose 38% to $49.7M, with R&D up 43% to $28.4M. The company plans to submit an FDA application for avexitide by year-end, targeting 160,000 U.S. patients with PBH. Amylyx is also advancing its pipeline, including AMX0318 and AMX0114, with a 2027 IND filing targeted for the former.

finance.yahoo.com
$AMLXMedAI 8/10

Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results

Amylyx Pharmaceuticals, Inc. (AMLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results • Reported positive topline results from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia; New Drug Application submission planned by end of 2026 remains on track • Results

SEC EDGAR 8-K
$AMLXLowAI 8/10

Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment

Amylyx Pharmaceuticals reported positive Phase III results for avexitide in treating PBH, with plans to file for FDA approval by year-end. The company estimates 160,000 U.S. patients with PBH, with 120,000 following Roux-en-Y gastric bypass. Management is preparing for a potential 2024 or 2027 launch, depending on the FDA label. Amylyx is also developing AMX0318 for PBH, targeting an IND filing next year.

finance.yahoo.com
$AMLXHighAI 8/10

Amylyx Stock Tumbles As Rally Meets Dilution Jitters

Amylyx Pharmaceuticals (AMLX) shares fell as investors took profits after a rally driven by positive Phase 3 data for avexitide. Concerns include valuation, dilution from a $500M stock offering, and insider sales. The company faces high funding needs for commercialization around 2027, shifting focus to financial costs and capital access.

tipranks.com
$AMLXHigh

Why Is AMLX Stock Popping 14% After Hours?

Amylyx Pharmaceuticals (AMLX) shares rose 14% after-hours as it prepares to release Phase 3 trial results for avexitide, its lead drug candidate for post-bariatric hypoglycemia. The trial's success could support a 2027 regulatory filing. AMLX has no FDA-approved therapies currently, and its cash runway extends into 2028. Mizuho raised its price target to $30, citing potential launch pricing updates.

stocktwits.com
$AMLXMedAI 8/10

Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?

Amylyx Pharmaceuticals (AMLX) has surged 247% this year after positive trial results for its experimental treatment, avexitide, which met all endpoints. The company aims to submit avexitide for FDA approval by year-end, with analysts estimating $1.5B in peak U.S. sales. Amylyx recently raised $500M through a stock offering. The stock is trading at $34.74, with a market cap of $4.2B.

fool.com